Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827945 | 0.88 | MAPT (0.78) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| Tretazicar SCHEMBL366755 | 0.88 | MAPT (1.00) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| Tretazicar SCHEMBL29375352 | 0.88 | MAPT (1.00) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL13685668 | 0.85 | MAPT (0.78) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL29391567 | 0.81 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL446497 | 0.81 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL3362694 | 0.81 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL6571188 | 0.79 | MAPT (0.68) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL27754610 | 0.79 | MAPT (0.68) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL23293826 | 0.78 | MAPT (0.67) | MAPTCYP3A4BLMPMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070166296-A1 | Therapeutic Systems | ENZACTA R & D LIMITED | 2007-07-19 | — | — | US | disclosed |
| US-7138122-B2 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-0988059-B8 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | PROTHERICS MOLECULAR DESIGN LT (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-0988059-B1 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| US-6867231-B1 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2005-03-15 | — | — | US | disclosed |
| EP-1468698-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20030086933-A1 | Therapeutic systems | ENZACTA R & D LIMITED | 2003-05-08 | — | — | US | disclosed |
| EP-0988059-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057662-A2 | THERAPEUTIC SYSTEMS | ENZACTA R & D LIMITED (GB) | 1998-12-23 | — | — | WO | disclosed |
| EP-0429454-A1 | IMPROVEMENTS RELATING TO THE CONTROL OF NEOPLASTIC TISSUE GROWTH | Roberts, John J. (GB) | 1991-06-05 | — | — | EP | disclosed |
| EP-0330432-A1 | Improvements relating to the control of neoplastic tissue growth | Roberts, John J. (GB) | 1989-08-30 | — | — | EP | disclosed |
| WO-1989007592-A1 | IMPROVEMENTS RELATING TO THE CONTROL OF NEOPLASTIC TISSUE GROWTH | ROBERTS JOHN J (GB) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070166296-A1 | Therapeutic Systems | NQO2, NQO1, NAPRT | MAPT 4009/4885CYP3A4 1278/4885BLM 3340/4885 |
| US-20030086933-A1 | Therapeutic systems | NQO2, NQO1, NAPRT | MAPT 4009/4885CYP3A4 1278/4885BLM 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.